193 related articles for article (PubMed ID: 37442062)
21. Different antiviral effects of IFNα and IFNβ in an HBV mouse model.
Zhou Y; Li S; Tang Z; Xu C; Huang S; Wu J; Dittmer U; Dickow J; Sutter K; Lu M; Yang D; Song J
Immunobiology; 2017 Mar; 222(3):562-570. PubMed ID: 27839836
[TBL] [Abstract][Full Text] [Related]
22. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
23. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.
Novotny LA; Evans JG; Su L; Guo H; Meissner EG
Viruses; 2021 Jun; 13(6):. PubMed ID: 34207487
[TBL] [Abstract][Full Text] [Related]
24. IFNα subtype-specific susceptibility of HBV in the course of chronic infection.
Xie X; Karakoese Z; Ablikim D; Ickler J; Schuhenn J; Zeng X; Feng X; Yang X; Dittmer U; Yang D; Sutter K; Liu J
Front Immunol; 2022; 13():1017753. PubMed ID: 36311794
[TBL] [Abstract][Full Text] [Related]
25. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes.
Alfaiate D; Lucifora J; Abeywickrama-Samarakoon N; Michelet M; Testoni B; Cortay JC; Sureau C; Zoulim F; Dény P; Durantel D
Antiviral Res; 2016 Dec; 136():19-31. PubMed ID: 27771387
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome-wide association study for persistent hepatitis B virus infection and related hepatocellular carcinoma.
Han J; Chen C; Wang C; Qin N; Huang M; Ma Z; Zhu M; Dai J; Jiang Y; Ma H; Jin G; Shen H; Hu Z
Liver Int; 2020 Sep; 40(9):2117-2127. PubMed ID: 32574393
[TBL] [Abstract][Full Text] [Related]
27. ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response.
Li T; Yang X; Li W; Song J; Li Z; Zhu X; Wu X; Liu Y
Mol Ther; 2021 Mar; 29(3):1335-1348. PubMed ID: 33279720
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic.
Yan SY; Fan JG; Qio L
Curr Cancer Drug Targets; 2017; 17(6):505-511. PubMed ID: 27677954
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
Zhang Z; Ni Y; Lempp FA; Walter L; Mutz P; Bartenschlager R; Urban S
J Hepatol; 2022 Oct; 77(4):957-966. PubMed ID: 35636579
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of SCAP inhibits HBV pathogenesis via activation of the interferon signaling pathway.
Makokha GN; Chayama K; Hayes CN; Abe-Chayama H; Abuduwaili M; Hijikata M
Virology; 2023 Aug; 585():248-258. PubMed ID: 37437369
[TBL] [Abstract][Full Text] [Related]
31. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
[TBL] [Abstract][Full Text] [Related]
32. Functional Comparison of Interferon-α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-α and Interferon-γ Signaling.
Chen J; Li Y; Lai F; Wang Y; Sutter K; Dittmer U; Ye J; Zai W; Liu M; Shen F; Wu M; Hu K; Li B; Lu M; Zhang X; Zhang J; Li J; Chen Q; Yuan Z
Hepatology; 2021 Feb; 73(2):486-502. PubMed ID: 32333814
[TBL] [Abstract][Full Text] [Related]
33. Clinical Relevance of HLA Gene Variants in HBV Infection.
Wang L; Zou ZQ; Wang K
J Immunol Res; 2016; 2016():9069375. PubMed ID: 27243039
[TBL] [Abstract][Full Text] [Related]
34. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
[TBL] [Abstract][Full Text] [Related]
35. Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma.
Niu Y; Chen L; Wu M; Huang W; Wu X; Huang D; Xie Y; Shi G
Virus Res; 2021 Feb; 293():198264. PubMed ID: 33359549
[TBL] [Abstract][Full Text] [Related]
36. Type-III interferon stimulated gene TRIM31 mutation in an HBV patient blocks its ability in promoting HBx degradation.
Xu F; Song H; Xiao Q; Wei Q; Pang X; Gao Y; Tan G
Virus Res; 2022 Jan; 308():198650. PubMed ID: 34863820
[TBL] [Abstract][Full Text] [Related]
37. Cytokine inhibition of the hepatitis B virus core promoter.
Romero R; Lavine JE
Hepatology; 1996 Jan; 23(1):17-23. PubMed ID: 8550037
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of HLA class I by inhibited replication of hepatitis B virus.
Takehara T; Hayashi N; Katayama K; Ueda K; Towata T; Kasahara A; Fusamoto H; Kamada T
J Hepatol; 1992 Mar; 14(2-3):232-6. PubMed ID: 1323597
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
